Carl Firth

Carl Firth is Founder and Chief Executive Officer of ASLAN Pharmaceuticals. Previously, he was Head of Asia Healthcare at Bank of America Merrill Lynch, supporting public and private financing of healthcare companies across the region and advising on M&A transactions.

Prior to joining the banking industry, Carl worked for AstraZeneca for 10 years in various commercial and R&D roles, including Regional Business Development Director AsiaPac and Director of New Product Development China.

Recently, Carl was chosen as one of SCRIP’s top 10 pharmaceutical leaders alongside notable industry veterans such as Ken Frazier, CEO of Merck, and Andrew Witty, CEO of GlaxoSmithKline.

Carl holds a PhD from Cambridge University in Molecular Biology (Trinity College), an Executive MBA from London Business School and a degree in Molecular Biology from Cambridge University.

Carl is an Independent Director of Hong Kong listed Uni-Bio Sciences and Singapore’s Exploit Technologies, and is also Adjunct Professor at Duke-NUS Medical School.

Carl Firth is the Founder & CEO at ASLAN Pharmaceuticals, based in Asia. With a background in Biotechnology, Carl Firth has a rich history of leadership and innovation. Carl Firth studied Ph.D. Computational simulation of cell signalling pathways @ University of Cambridge. Explore their detailed professional journey, key connections, and contributions to the industry on our platform.